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Catharina C. M. Schuiling-Veninga5, Paul F. M. Krabbe12 and Maarten J. Postma1,3,5,12,13,14Abstract
Background: The EuroQoL five-dimensional instrument (EQ-5D) is the favoured preference-based instrument to
measure health-related quality of life (HRQoL) in several countries. Two versions of the EQ-5D are available: the 3-level
version (EQ-5D-3 L) and the 5-level version (EQ-5D-5 L). This study aims to compare specific measurement properties
and scoring of the EQ-5D-3 L (3 L) and EQ-5D-5 L (5 L) in Indonesian type 2 diabetes mellitus (T2DM) outpatients.
Methods: A survey was conducted in a hospital and two primary healthcare centres on Sulawesi Island. Participants
were asked to complete the two versions of the EQ-5D instruments. The 3 L and 5 L were compared in terms of
distribution and ceiling, discriminative power and test-retest reliability. To determine the consistency of the participants’
answers, we checked the redistribution pattern, i.e., the consistency of a participant’s scores in both versions.
Results: A total of 198 T2DM outpatients (mean age 59.90 ± 11.06) completed the 3 L and 5 L surveys. A total of 46
health states for 3 L and 90 health states for 5 L were reported. The ‘11121’ health state was reported most often: 17%
in the 3 L and 13% in the 5 L. The results suggested a lower ceiling effect for 5 L (11%) than for 3 L (15%). Regarding
redistribution, only 6.1% of responses were found to be inconsistent in this study. The 5 L had higher discriminative
power than the 3 L version. Reliability as reflected by the index score was 0.64 for 3 L and 0.74 for 5 L. Pain/discomfort
was the dimension mostly affected, whereas the self-care dimension was the least affected.
Conclusions: This study suggests that the 5 L-version of the EQ-5D instrument performs better than the 3 L-version in
T2DM outpatients in Indonesia, regarding measurement and scoring properties. As such, our study supports the use of
the 5 L as the preferred health-related quality of life measurement tool.
We did not do a trial but this study was approved by the Medical Ethics Committee of Universitas Gadjah Mada
Yogyakarta, Indonesia (document number KE/FK/1188/EC, 12 November 2014, amended 16 March 2015).© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
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(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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In 2011, the number of people suffering from diabetes
mellitus (DM) in the world was reported at 366 million
[1]. Based on the latest data in 2017, this number has in-
creased by almost 20% to reach 450 million [2]. World-
wide, 90% of these suffer from type 2 diabetes mellitus
(T2DM) [3]. In Indonesia, in the same period mentioned,
the number of people with T2DM even increased by 30%,
i.e., from 7.3 million to 10.3 million [1, 2]. In this respect,
the Indonesian Ministry of Health also reported that the
national prevalence of T2DM in Indonesia had almost
doubled from 1.1% in 2007 to 2.1% in 2013 [4]. Further-
more, the Ministry of Health’s report stated that of the 34
provinces in Indonesia, 15 provinces had a higher preva-
lence of T2DM patients than the national average, inclu-
sive Sulawesi island [4]. Notably, the prevalence of T2DM
amounts to 3.7% in Central Sulawesi province, 3.6% in
North Sulawesi and 3.4% in South Sulawesi [4]. The con-
tinued increase in the prevalence of T2DM patients in
Indonesia requires serious attention, especially concerning
control of T2DM costs and patients’ health status and
cost-effectiveness of interventions. In this respect,
adequate measurement of health-related quality of life
(HRQoL) reflects a core issue.
The EuroQoL five-dimensional instrument (EQ-5D) is
the recommended preference-based instrument to meas-
ure HRQoL in several countries [5, 6]. HRQoL is mea-
sured by this instrument in such a way that it generates
a single index score or utility. This instrument consists
of five items covering five health-state dimensions (mo-
bility, self-care, usual activities, pain/discomfort, and
anxiety/depression), with each item originally having
three levels of severity (EQ-5D-3 L) [7]. In 2011, the
EuroQol Group expanded the number of severity levels
for each dimension to five (EQ-5D-5 L) [8]. Both the
EQ-5D-3 L (3 L) and EQ-5D-5 L (5 L) versions have been
used in several studies, covering both clinical and meth-
odological assessments [8–10].
Several comparative studies of the 3 L and 5 L versions
of EQ-5D have been conducted in the countries neigh-
bouring Indonesia, notably Singapore and Thailand.
Both studies reported that 5 L is the preferable version
for T2DM patients considering its greater discriminative
power and patients’ preferences [11, 12]. Considering
the 5 L and 3 L versions, it is noted that both versions
have been used in several studies in Indonesia, already,
but a structured, integrative and direct comparison is
still lacking [13–16], however a structured integrative
comparison is still missing, motivating the conduct of
our study. Whereas such comparisons would be available
for other countries, sociodemographic characteristics
and cultural differences between Indonesia and other
countries might differ potentially resulting in varying
findings measurement properties of the two EQ-5Dversions. Therefore, this study aims to directly compare
specific measurement properties and scorings of the 3 L




A cross-sectional study was conducted from July 2016 to
April 2017. A secondary care setting in South Sulawesi
and two primary care settings in Central Sulawesi were
included. In particular, these were Jaury Academic Hos-
pital in Makassar and the Puskesmas/primary healthcare
centers (PHCs) in Simpong and Kampung Baru in
Luwuk Banggai, respectively. This study was approved
by the Medical Ethics Committee of Universitas Gadjah
Mada Yogyakarta, Indonesia (document number KE/FK/
1188/EC, 12 November 2014, amended 16 March 2015).
Participants
Participants were T2DM outpatients with a minimum age
of 18 years. The participants were informed of the study
objectives and study procedure. The researcher or re-
search assistants obtained signed informed consent forms
from the participants. For the participants with disabilities
or difficulties in reading, consent was based on confirm-
ation from their caregiver who accompanied them during
treatment at a health facility. The caregiver played a role
in providing support to the participants as they filled in
the instruments. It is important to note that all decisions
on the exact health states chosen originated from the par-
ticipants. In this study, all participants were treated by a
consulting resident internal medicine who gave his/her
consent to the data collection during the participant’s
T2DM consultation (in primary and secondary care).
Instruments
EQ-5D 3 L and 5 L consist of two parts: the EQ-5D de-
scriptive system classification and the EQ visual analogue
scale (EQ-VAS). The EQ-5D descriptive system comprises
five items on its HRQoL dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
Each dimension in the 3 L version [10] is completed with
three response options: no problem, some problems, and
confined to bed/unable/extreme problems, yielding a pos-
sible 243 (35) unique health states. A single digit expresses
the level selected for that specific dimension. Therefore,
the five-digit number for five dimensions describes a spe-
cific health state. For example, ‘11111’ indicates ‘no prob-
lems on any of the five dimensions’, while ‘23231’ indicates
‘some problems walking, unable to wash or dress, some
problems with performing usual activities, extreme pain/
discomfort, and no anxiety/depression’. The 5 L [8] has
five scale options to choose from: no problem, slight prob-
lems, moderate problems, severe problems, and extreme
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unique health states. For example, ‘12345’ indicates ‘no
problems walking, slight problems washing or dressing,
moderate problems doing usual activities, severe pain/dis-
comfort and extreme anxiety/depression’. The EQ-VAS
presents the participants’ self-rated health on a scale of 0
(worst imaginable health) to 100 (best imaginable health).
The time frame for the EQ-VAS is ‘today’, meaning that
participants were asked to describe their health state dur-
ing the day they were interviewed. We used the 3 L and 5
L Bahasa Indonesia versions of the EQ-5D, produced by
the EuroQol Group using a standardized translation proto-
col [17] and having been proved as valid and reliable ques-
tionnaires in Indonesian patient groups [13–16].
Data collection procedure and data sources
After introducing the researchers and explaining the
purpose of the study, a brief description to the partici-
pants was provided on how to use the EQ-5D instru-
ments. An explanation of the concept of HRQoL as an
aid on how they should describe their health state was
presented. The participants were given the opportunity
to ask questions throughout the data collection process.
For EQ-VAS, we asked the participants to describe their
health state and provide the most appropriate score to
define their health state. Three research assistants were
hired to collect the data. As a sequence, participants first
classified their health state on the 5 L items, then pro-
vided their data (sociodemographic and clinical condi-
tions), followed by the 3 L.
According to socio-demographic data (gender, age,
T2DM duration, occupation, level of education, and de-
pendence on a caregiver) were obtained from self-
reporting. In this study, participants were classified into
two age categories based on the retirement age of Indo-
nesian people (56 years): productive age (below 56 years)
and retirement age (56 years and above). As for employ-
ment status, participants were defined as in active em-
ployment when they were still actively working, and
unemployed if they reported not having a job. Those
whose main responsibilities were for their family mem-
bers and household chores were classified as housewives.
Data on the clinical conditions, such as the type of
therapy, T2DM-related complications, and comorbidities
were obtained from treating physicians. Self-reported
data from participants was used in the cases data could
not be collected through the treating physicians. In this
study, participants were defined as having comorbidities
if they suffered from other diseases, such as asthma, gas-
tritis and gout problems. Participants were defined as
having complication and comorbidities if they suffered
from other diseases and T2DM complications; for ex-
ample, a participant with comorbid cancer and hyper-
tension as a complication of diabetes.Test-retest reliability
Test-retest reliability was analyzed using sequential mea-
surements. Participants involved in this phase were those
who visited the specific health facility twice. The time
interval between the two measurement times was four
weeks as the participants were scheduled to meet their
consulting resident internal medicine each month. Not-
ably, an additional question was asked before the partici-
pants completed the instruments the second round: ‘Has
there been any major change in your health state be-
tween the first time you completed the instruments last
month and today? For example, have you been hospita-
lised, had an accident, experienced a natural disaster or
have been bereaved’? Participants who answered ‘yes’
were excluded from the final sample.
Analyses
For self-reported health state profiles obtained from the
two versions of EQ-5D, we calculated the percentage of
participants who responded to each level of each dimen-
sion. To determine the consistency of the participants’
answers, we checked the redistribution pattern, i.e., the
consistency of individual participants’ scores in both
versions. A consistent response pair was defined as a 3 L
response which is at most one level away from the 5 L
response (e.g., a participant chose level 1 in 3 L and
chose level 2 in 5 L). When the 5 L level was more than
1 level away from the 3 L level (e.g., a participant chose
level 1 in 3 L and chose level 3 in 5), this was labelled in-
consistent [11]. Next, we converted their scores on 3 L
to 5 L as follows: 1 in 3 L equals 1 in 5 L, 2 in 3 L equals
3 in 5 L, and 3 in 3 L equals 5 in 5 L [12]. The ceiling ef-
fect was defined as the proportion of participants who
reported not having problems in any of the five EQ-5D
dimensions (health state ‘11111’) for both 3 L and 5 L.
This statistic is often used to assess the discriminatory
power of health-state classification systems [18, 19]. As
Indonesia only has the EQ-5D-5 L value set, not the 3 L
[20], to obtain consistent 3 L and 5 L utility index scores,
the UK 3 L and 5 L value sets [21, 22] were used.
The test-retest reliability of the dimension scores was
assessed using the weighted kappa. We applied Landis JR
& Koch GG standards [23] to determine the strength of
agreement of the kappa values as follows: < 0.00 = poor,
0.00–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 =moderate,
0.61–0.80 = substantial, and 0.81–1.00 = almost perfect
[20]. The test-retest reliability of the EQ-VAS and index
scores were calculated using intra-class correlation coeffi-
cients (ICCs), two-way random effects and absolute agree-
ments. The following reliability guideline was used for the
strength of the ICC values: < 0.5 = poor, 0.5–0.75 =moder-
ate, 0.75–0.90 = good and > 0.90 = excellent [24]. The dis-
criminative power was calculated using the Shannon
index (H′) and Shannon’s Evenness index (J’) [18, 19].
Table 1 Sociodemographic characteristics, clinical conditions
and participants’ preferences
Variables Overall (n = 198)
n (%)
Sociodemographic characteristics
Mean age (year) ± SD 59.90 ± 11.06
Age*
Less than 56 70 (35)






Primary school 33 (16)
Junior high school 42 (21)
Senior high school 83 (42)










Diet or no OAD or insulin in the R/** 20 (10)
OAD (mono and combinations) 143 (72)










Micro & macrovascular 7 (3)
Number of T2DM complications
No 74 (38)
One complication 76 (39)
Two or more 27 (13)
*We choose 56 years as the cut-off point because that is the pension
age in Indonesia
aParticipants were defined as having comorbidities if they suffered from
other diseases (not T2DM complications)
bParticipants were defined as having complication and comorbidities if
they suffered from other diseases and T2DM complications
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content as expressed by the number of categories with the
extent to which the information is evenly spread over
these categories. On the other hand, the J’ expresses the
relative information of a system or the evenness of the in-
formation distribution regardless of the number of cat-
egories. In case of an even distribution, when all levels are
filled with the same frequency, J’ is equal to 1. Larger H′
and J’ values indicate more discriminatory performance.
All the data were analysed using IBM SPSS Statistics for
Windows version 23 (SPSS Inc., Cambridge, MA, USA),
and statistical significance was set a priori at p < .05.
Results
Descriptive
A total of 198 participants were interviewed (Table 1).
The average age of the participants was almost 60 years,
with 58% being female, and 70% of female participants re-
ported being housewives as their main activity. Regarding
the clinical conditions, more than 70% of participants
were being treated with oral antidiabetic therapy (OAD),
both monotherapy and OAD combinations, and 52% of
participants reported T2DM-related complications. Fur-
thermore, participants had various comorbidities, such as
asthma (n = 6), gastritis (n = 5), and gout (n = 3).
For test and re-test reliability, of the 198 participants
who completed the first survey, 53 participants (62% fe-
male) completed the instruments twice. In this phase,
only 12 participants had a university degree and most of
the female participants were housewives (n = 20). Fur-
thermore, of the almost 70% of participants treated with
OADs, 40% reported T2DM without complications and
36% reported T2DM with at least one complication.
There were no missing health state data.
Scoring and ceiling
Participants usually reported no problems (level 1) on both
3 L and 5 L, except for the pain/discomfort dimension with
only 25 and 20% of participants reporting no problems on
3 L and 5 L, respectively. Therefore, pain/discomfort was
more often reported at other 3 L and 5 L levels compared
to the other EQ-5D dimensions (Table 2).
Regarding the ceiling effect, the 5 L version showed
slightly fewer reports of absence of problems in all di-
mensions (‘11111’) compared to the 3 L version. The
percentage of participants reporting the ‘11111’ health
state decreased from 15% in the 3 L to 11% in the 5 L.
Nevertheless, no statistically significant difference was
found (p-value = .178). Self-care reached the highest ceil-
ing (82% for the 3 L, 78% for the 5 L) while pain/discom-
fort showed the lowest ceiling (as mentioned above, 25%
for the 3 L, 20% for the 5 L). The anxiety/depression di-
mension showed the smallest reduction in the ceiling
(3% less), whereas the mobility dimension showed the
Arifin et al. Health and Quality of Life Outcomes           (2020) 18:22 Page 5 of 9largest reduction (7% reduction) when going from 3 L to
5 L. None of the ceiling reductions from 3 L to 5 L were
statistically significant.
The range of index scores was broader in the 3 L than
in the 5 L version, especially for negative values (Fig. 1).
The lowest index score reported for the 3 L was − 0.349
(state ‘23333’), whereas this was − 0.263 (state ‘45554’)
for the 5 L. The most frequently reported health state
was ‘11121’ (slight problems in pain/discomfort and no
problems in the other dimensions), i.e. 17% in the 3 L
and 13% in the 5 L. There were 46 and 90, 3 L and 5 L
health states reported in the study, respectively.
Redistribution from 3 L to 5 L
Of the participants who reported no problem (level 1) for
a dimension on the 3 L, most (73–94%) reported the same
on the 5 L, while 6–26% switched to slight problems (level
2) on the 5 L as shown in Table 3. The majority of the par-
ticipants who reported moderate problems (level 2) on the
3 L indicated slight problems (level 2) on the 5 L (44–
67%), while 20–28% switched to moderate problems (level
3) and 12–31% shifted to severe problems (level 4) on the
5 L. Most of the participants who indicated confined to
bed/unable/extreme problems (level 3) on the 3 L indi-
cated extreme problems (level 5) on the 5 L for the usual
activities dimension, whereas most participants who re-
ported extreme problems on 3 L redistributed into severe
problems (level 4) for pain/discomfort and anxiety/depres-
sion. As for the self-care dimension, these percentages
were equal. Redistribution occurred least frequently in the
mobility dimension since no participant reported ‘con-
fined to bed’ on the 3 L in that area. The inconsistent re-
sponses were ranging from 4% on self-care to 7.6% on the
pain/discomfort and anxiety/depression dimensions. An
example of such inconsistency was a participant choosing
‘no problems walking’ in 3 L (mobility level 1) and ‘severe
problems walking’ in 5 L (mobility level 4).Table 2 Self-reported health on the EQ-5D-3 L and EQ-5D-5 L descr
EQ-5D-3 L EQ-5D








Mobility 58.38 41.62 0.00 5
Self-care 82.23 16.75 1.02 7
Usual activities 67.51 28.43 4.06 6
Pain/ discomfort 25.38 59.90 14.72 1
Anxiety/
depression
46.70 44.67 8.63 4
Mean EQ-VAS (SD) 74.71 (20.13) 74.81
25% percentile 60.00 60.00
50% percentile 75.00 75.00
75% percentile 90.00 90.00
VAS Visual analogue scaleDiscriminative power
Compared to the 3 L version, the 5 L system had a sub-
stantial gain in classification efficiency for each dimen-
sion, indicated by higher H′ values of all the dimensions.
The J’ values were more similar among the two versions
of EQ-5D as shown in Table 4, indicating that the de-
gree of the potential use of the classification system was
comparable between the two versions.
Test-retest reliability
Fifty-three participants (26.8%) completed the instruments
twice. By inclusion criterion, all reported no major
changes in their health between the first and second data
completion point. The weighted kappa of the 5 L dimen-
sions for the 3 L was judged as slightly in agreement for
the self-care dimension at 0.14, while the other four di-
mensions fair agreement existed: mobility at 0.25, usual
activities at 0.23, pain/discomfort at 0.25 and anxiety/de-
pression at 0.40. For the 5 L, the pain/discomfort dimen-
sion was judged as slightly in agreement at 0.19, while the
other four dimensions were in fair agreement: mobility at
0.35, self-care at 0.30, usual activities at 0.37 and anxiety/
depression at 0.39. The EQ-VAS ICCs were 0.35 and 0.32
for the 3 L and 5 L respectively. Moreover, the ICCs of the
3 L and 5 L index scores were 0.64 and 0.74 respectively,
reflecting a moderate level of reproducibility (Table 5).
Discussion
We examined some important specific measurement prop-
erties of the 3 L and 5 L instruments in Indonesian T2DM
outpatients. We found that the 5 L version had a lower
ceiling effect, higher discriminative power, and in the ma-
jority of the dimensions a higher test-retest reliability coef-
ficient compared to the 3 L. The 5 L classification system
better represents the variety of patients’ health states,
showed by the more health states reported in the 5 L than











0.51 24.24 12.62 11.62 1.01
8.28 12.63 5.05 3.03 1.01
3.64 18.18 7.58 7.07 3.54
9.70 40.91 18.18 17.17 4.04
3.43 33.84 12.63 8.00 2.02
(19.70)
Fig. 1 Cumulative percentage of the EQ-5D-3 L and EQ-5D-5 L index scores
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to the 3 L, indicated by the gain of the Shannon H′ index
from 3 L to 5 L. These results were similar to the findings
from across the globe, as reviewed by Buchholz et al. [25].
The J’ index was also in line with the results of the afore-
mentioned study.
The 5 L version showed a lower ceiling effect (health
state ‘11111’) than the 3 L at 11 and 15%, respectively.
Notably, a previous study [25] suggested that a ceiling ef-
fect of 15% and higher should be considered as ‘serious’
(as shown for the 3 L version) while relevantly below 15%
is considered small (as shown by the 5 L version). Several
studies suggested that other HRQoL instruments have
shown lower ceiling effects than the EQ-5D while still
strongly correlated with the EQ-5D scores, e.g. the SF-6D
[26, 27]. Also, Round suggests to consider other HRQoL
measures instead of EQ-5D [28]. However, in several
countries, including Indonesia, EQ-5D is the recom-
mended preference-based instrument to measure HRQoL.
Therefore, a lower ceiling effect as shown by the 5 L ver-
sion supports the use of EQ-5D-5 L in Indonesia, espe-
cially in patients with T2DM.
Next to better statistical properties, during discussions,
also our participants stated that in the 5 L they could more
accurately describe their own health state and the severity
of T2DM. This is in line with studies in Thailand and
Singapore which also stated in both studies that DM sever-
ity could be better described in 5 L compared to 3 L [11,
12]. Therefore, our study provides further support to advo-
cate the use of 5 L in clinical, health policy and economicevaluation studies with EQ-5D index score assessments; in
our case, notably for Indonesian T2DM outpatients.
Another finding of our research concerns the fact that
most participants reported problems on pain/discomfort
dimension in the 3 L and 5 L. Notably, the ‘11121’ was
the most reported health state by the participants. Four
previous studies in Asian populations with T2DM also
reported similar findings [12, 29–31]. Also, a multi-
country study stated that the Eastern European partici-
pants had three times higher mobility and usual activity
problems and six times higher self-care problems com-
pared to their Asian counterparts [32].
In this study, the inconsistent responses were ranging
from 4% (self-care) to 7.6% (pain/discomfort and anxiety/
depression). This was slightly higher than in the studies in
China and Singapore at 0.7–1.4% and 2.5–4.1%, respect-
ively. A similar study in Thailand resulted in no inconsist-
ent response at all. It could be argued that higher education
level, younger age, and more healthy DM patients (without
complications or comorbidities) might play a role in this
difference, which indeed seems the case in Thailand study.
However, the age distributions and education levels of our
participants were overall similar with those in the China
and Singapore studies. A possible explanation offered is
that the difficulties faced by our elderly participants in
completing the 5 L produced these inconsistent responses,
although we assisted with explanations. Notably, many eld-
erly participants experienced decreased vision and hearing
loss, especially participants in the secondary care facilities.
Also, many Indonesian T2DM patients had low levels of
Table 3 Redistribution pattern of response from 3 L to 5 L
Dimension 3 L 5 L N (%) by 3 L level Inconsistencies* N (%)
Mobility 1 1 94 (73.08) 11 (5.5)
2 19 (26.92)
2 2 29 (44.74)
3 23 (23.68)
4 22 (31.58)
Self-Care 1 1 150 (93.75) 8 (4.0)
2 10 (6.25)
2 2 15 (53.57)
3 8 (28.57)
4 5 (17.86)
3 4 1 (50.00)
5 1 (50.00)
Usual Activities 1 1 117 (89.31) 11 (5.5)
2 14 (10.69)
2 2 22 (45.84)
3 13 (27.08)
4 13 (27.08)
3 4 1 (12.50)
5 7 (87.50)
Pain/Discomfort 1 1 34 (75.55) 15 (7.6)
2 11 (24.45)
2 2 68 (59.65)
3 28 (24.56)
4 18 (15.79)
3 4 15 (65.22)
5 8 (34.78)
Anxiety/Depression 1 1 80 (88.89) 15 (7.6)
2 10 (11.11)
2 2 56 (67.47)
3 17 (20.48)
4 10 (12.05)
3 4 6 (60.00)
5 4 (40.00)
*A consistent response pair was defined as a 3 L response which is at most
one level away from the 5 L response (e.g., a participant chose level 1 in 3 L
and chose level 2 in 5 L). When the 5 L level was more than 1 level away from
the 3 L level (e.g., a participant chose level 1 in 3 L and chose level 3 in 5), this
was labelled inconsistent
Table 4 Shannon’s index (H′) and (J’) of 3 L and 5 L
Dimension H′ J’
3 L 5 L 3 L 5 L
Mobility 0.68 1.25 0.43 0.54
Self-care 0.54 0.76 0.34 0.33
Usual activities 0.77 1.10 0.48 0.47
Pain/discomfort 0.94 1.43 0.59 0.62
Anxiety/depression 0.95 1.27 0.60 0.55
Table 5 Weighted Kappa and ICC of test-retest
Dimensions Weighted Kappa
EQ-5D-3 L EQ-5D-5 L
Mobility 0.25 0.35
Self-care 0.14 0.30




VAS scores 0.35 0.32
Index scores 0.64 0.74
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the EQ-5D instrument was a necessity.
Our study has some limitations which should be con-
sidered. First, the participants were recruited from only
two locations in Indonesia. Therefore, generalizing the
findings nationally should be done with caution. Sec-
ond, only outpatient participants were recruited for this
study. These findings may not be generalizable toinpatients who probably experience more health diffi-
culties: i.e. would report worse health states. Future
investigations could include the inpatients to comple-
ment the analysis that we provide. Another limitation is
that we did not randomize the order of the two ver-
sions of the EQ-5D instrument. One could argue that
the presentation of 5 L first followed by the 3 L for all
participants might produce some bias in the answers of
the participants. Our reason was to limit the tendency
to not use level 2 and 4 in 5 L [33]. Also, this order was
also used in other comparative studies, such as those in
Thailand [12], Singapore [11] and one multi-country
study Denmark, England, Italy, the Netherlands,
Poland, and Scotland [34].
Finally, it is noteworthy that, during our discus-
sions, is seemed that participants with lower educa-
tion levels and elderly participants preferred the 3 L
version, often mentioning that the 3 L version was
easier to understand, despite all explanations provided
and the flexibility of the 5 L version to more precisely
express the health state. Obviously, these patients’
preferences come in as an additional important aspect
and warrants further research in this area, inclusive
options to even better convey the 5 L version to par-
ticipants. Finally, further research should focus on
other areas in Indonesia beyond our index area of
Sulawesi; for example, a similar type of investigation
on Java would be worthwhile, with the majority of
the Indonesian population living there.
Arifin et al. Health and Quality of Life Outcomes           (2020) 18:22 Page 8 of 9Conclusion
This study suggests that the 5 L-version of EQ-5D per-
forms better than the 3 L-version in T2DM outpatients
in Indonesia. As such, our study supports the use of the
5 L as the preferred HRQoL tool to derive EQ-5D index
scores, which are indispensable in pharmacoeconomic
analyses and health economic evaluations of interven-
tions in T2DM patients.
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